Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

1753 - Treatment Outcome of gastric cancer associated with esophageal cancer

Date

09 Sep 2017

Session

Poster display session

Topics

Oesophageal Cancer;  Gastric Cancer

Presenters

Naoki Mori

Citation

Annals of Oncology (2017) 28 (suppl_5): v209-v268. 10.1093/annonc/mdx369

Authors

N. Mori, T. Tanaka, S. Matono, Y. Akagi

Author affiliations

  • Surgery, Kurume University School of Medicine, 830-0011 - Kurume/JP
More

Resources

Abstract 1753

Background

The incidence of synchronous and metachronous gastric cancer is high in esophageal cancer patients.

Methods

113 esophageal cancer (EC) patients with synchronous and metachronous gastric cancer (GC) were analyzed between 1997 and 2016 retrospectively. There were 110 men and 3 women, with a median age of 67 years. 58 had a synchronous gastric cancer (S group) and 55 had a metachronous (M group). In the M group, there were 36 patients with a subsequent esophageal cancer (SEC) and 19 with an antecedent esophageal cancer (AEC).

Results

1) S group: T stage of EC was 1 in 14 patients, 2 in 4, 3 in 25, and 4 in 15. Stage was 0 in 4 patients, I in 6, II in 9, and III in 39. T stage of GC was 1 in 46 patients, 2 in 6, 3 in 4, and 4 in 2. Stage was I in 49 patients, II in 5, and III in 4. 35 underwent esophagectomy (31 gastrectomy and 4 endoscopic treatments) and 23 received definitive chemo-radiotherapy for EC (4 gastrectomy, 3 endoscopic treatments, and 16 observations for gastric cancer). 2) SEC group: The median range between gastrectomy and esophageal treatment was 8.4 years. T stage of EC was 1 in 13 patients, 2 in 6, 3 in 11, and 4 in 6. Stage was I in 3 patients, II in 8, and III in 25. Of the 36 pts, 16 underwent esophagectomy, 18 received definitive (chemo-) radiotherapy, and 2 underwent endoscopic treatment. 3) AEC group: The median range between esophagectomy and gastric treatment was 6.5 years. T stage of EC was 1 in 6 patients, 2 in 1, and 3 in 8, and 4 in 4. Stage was I in 6, II in 6, and III in 7. T stage of GC was 1 in 11 patients, 2 in 4, and 3 in 4. Of 19, 10 underwent endoscopic treatment, 5 underwent gastrectomy, 1 received chemotherapy, and 1 did not receive any anti-cancer treatment. The overall survival rates at 5 years in S group, SEC group, and AEC group were 50%, 45%, and 51%, respectively. There was a significant difference in the overall survival rates between the surgery group (45%) and non-surgery group (36%) in the S group (p = 0.0006). In the SEC group, there was a tendency of long survival in those who underwent surgery (56%), compared to those who did not have surgery (37%) (p = 0.06). Prognosis of patients with gastric tube cancer was 10 years after EC treatment and 4 years after gastric tube cancer treatment.

Conclusions

Patients in the S group who underwent surgery had a good prognosis. Periodic endoscopic examination is necessary for early diagnosis of gastric tube cancer.

Clinical trial identification

Legal entity responsible for the study

Kurume University School of Medicine

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.